Showing results (351-360 of 793) with videos related to

Sort By:
Pageof 80
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Cancer|August 18, 2017
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myelomaJatin J Shah, Jonathan L Kaufman, Jeffrey A Zonder, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 29, 2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory CommitteeNoopur Raje, Beth Faiman, R Donald Harvey, et al.
Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Plos One|May 11, 2023
RWD-derived response in multiple myelomaTao Xu, James Roose, Mellissa Williamson, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2016
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?Zachariah DeFilipp, Amelia A Langston, Zhengjia Chen, et al.
Blood Cancer Journal|October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 studyPaul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Pageof 80